Publications

Cancer research

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

01-12-2009

Cancer treatment reviews

High-grade glioma mouse models and their applicability for preclinical testing.

01-12-2009

Molecular cancer therapeutics

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.

01-12-2009

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

01-11-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

01-05-2009

Investigational new drugs

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

01-02-2009

Current clinical pharmacology

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

01-01-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

15-12-2008

Drug metabolism and disposition: the biological fate of chemicals

Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.

01-08-2008

Molecular cancer therapeutics

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

01-08-2008

Molecular cancer therapeutics

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

01-12-2007

The Journal of clinical investigation

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

01-11-2007

Biomedical chromatography : BMC

Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

01-11-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

01-11-2007

Cancer cell

Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.

01-10-2007

Proceedings of the National Academy of Sciences of the United States of America

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

17-07-2007

Biomedical chromatography : BMC

Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.

01-07-2007

Investigational new drugs

Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

01-02-2007

European journal of cancer (Oxford, England : 1990)

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.

01-12-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

15-10-2006

Expert review of neurotherapeutics

Blood-brain barrier and chemotherapeutic treatment of brain tumors.

01-08-2006

Cold Spring Harbor symposia on quantitative biology

Genotype-phenotype relationships in a mouse model for human small-cell lung cancer.

28-07-2006

The Journal of pharmacology and experimental therapeutics

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

01-07-2006

Cancer chemotherapy and pharmacology

The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.

01-06-2006

International journal of cancer

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

20-09-2005

Cancer chemotherapy and pharmacology

Metabolism of docetaxel in mice.

01-09-2005

Analytical and bioanalytical chemistry

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.

01-08-2005

Cancer research

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

01-04-2005

Journal of mass spectrometry : JMS

A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.

01-12-2004

Cancer research

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

15-08-2004

Cancer treatment reviews

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

01-08-2004

Investigational new drugs

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

01-08-2004

European journal of cancer (Oxford, England : 1990)

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

01-05-2004

Cancer chemotherapy and pharmacology

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.

01-02-2004

Analytical biochemistry

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

01-01-2004

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

05-12-2003

British journal of cancer

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

03-11-2003

Laboratory animals

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.

01-07-2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

01-07-2003

Cancer research

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

15-03-2003

Anti-cancer drugs

Metabolism of paclitaxel in mice.

01-03-2003

Anti-cancer drugs

Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.

01-01-2003

Cancer research

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

01-11-2002

Cancer chemotherapy and pharmacology

A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.

01-07-2002

Molecular cancer therapeutics

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

01-04-2002

Cancer chemotherapy and pharmacology

Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.

01-02-2002

British journal of cancer

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

16-11-2001

Journal of chromatography. B, Biomedical sciences and applications

Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.

05-11-2001

Journal of chromatography. B, Biomedical sciences and applications

Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.

05-08-2001

Cancer chemotherapy and pharmacology

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.

01-04-2001